Features | Partner Sites | Information | LinkXpress
Sign In
PURITAN MEDICAL
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Cancer Immunotherapy Sector Predicted to Surge to USD 9 Billion Across Major Pharma Through 2022

By BiotechDaily International staff writers
Posted on 30 Jul 2014
The immunotherapy market will experience substantial growth through 2022, increasing from USD 1.1 billion in 2012 to nearly USD 9 billion in 2022 (corresponding to 23.8% annual growth) in the United Kingdom, United States, France, Germany, Italy, Spain, and Japan, according to recent market research.

This notable growth will be fueled by the anticipated market entry of nine novel immunotherapies--including four novel immune checkpoint inhibitors and five novel therapeutic vaccines—in new oncology indications and/or patient populations, according to Decision Resources Group (Burlington, MA, USA). Combined, Bristol-Myers Squibb’s anti-CTLA-4 agent Yervoy and innovative immune checkpoint inhibitors that target the anti-programmed cell death-1/programmed death-ligand-1 (PD-1/PD-L1) pathway—including Bristol-Myers Squibb/Ono Pharmaceutical’s nivolumab, Merck & Co.'s pembrolizumab (MK-3475), Roche/Genentech/Chugai’s MPDL-3280A and AstraZeneca/MedImmune’s MEDI4736—should dominate the immunotherapy market and capture a remarkable 85% market share in 2022.

Other key findings from the Pharmacor Immunotherapies advisory service include: potential of anti-PD-1/PD-L1 agents: Interviewed experts are considerably excited about the potential of anti-PD-1/PD-L1 agents based on encouraging data released to date in multiple oncology indications. The added prospect of using PD-L1 expression as a potential predictive biomarker for customizing treatment fascinated interviewed experts; however, they remain watchful on this point, noting that considerable heterogeneity exists in PD-L1 expression and that good objective responses have also been reported in patients considered to have no or low levels of PD-L1 expression.

Because of the impressive early-phase data presented at the 2014 annual meeting of the American Society for Clinical Oncology (ASCO), held May 30-June 3, 2014, in Chicago (IL, USA), interviewed experts expressed enthusiasm for combination approaches involving immunotherapies—including dual blockade of the immune checkpoint pathway, combinations of immune checkpoint inhibitors with therapeutic cancer vaccines and combinations of immune checkpoint inhibitors with chemotherapy.

The therapeutic vaccines segment will see, according to Decision Resources Group, 13.6% annual sales growth over the 2012 to 2022 forecast period, although, with combined major-market sales reaching USD 1.2 billion in 2022, these agents will not reach the commercial success of immune checkpoint inhibitors.

Decision Resources Group senior business insights analyst Khurram Nawaz, MSc, commented, “A plethora of immunotherapies are in development across a wide range of oncology indications, making this drug class one of the most exciting to watch. We anticipate that nivolumab will be the sales-leading agent among immunotherapies. However, it will face direct and intense competition from other anti-PD-1/PD-L1 agents—notably from pembrolizumab in malignant melanoma and non-small-cell lung cancer—and to a lesser degree, from MPDL-3280A in non-small-cell lung cancer. Interviewed experts express mixed reactions to therapeutic vaccines and note the challenges in monitoring the efficacy of these agents. Nevertheless, they are hopeful that some vaccines will provide new therapeutic options and hold greatest promise as part of combination strategies.”

Decision Resources Group offers information and insights on critical issues within the healthcare industry.

Related Links:

Decision Resources Group



Channels

Genomics/Proteomics

view channel
Image: Nomarski interference contrast photomicrographs of Cryptosporidium in the feces of an HIV-positive human (Photo courtesy of the CDC - [US] Centers for Disease Control and Prevention).

Advanced Genetic Tools Revamp Search for Drugs to Treat Cryptosporidium

Genetically engineered modifications to genome of the diarrhea-causing parasite Cryptosporidium are expected to expedite research towards vaccine and drug development to prevent or cure infection by this pathogen.... Read more

Drug Discovery

view channel
Image: A new micelle delivery system for the protective polyphenols resveratrol and quercetin (mRQ) may have value in cancer chemotherapy (Photo courtesy of Oregon State University).

Micelles Containing Resveratrol and Quercetin Reverse Doxorubicin Cardiotoxicity

Cancer researchers blocked the toxic effects of the cancer drug doxorubicin (DOX) by administering it together with the plant antioxidants resveratrol and quercetin. Although in use for more than 40... Read more

Lab Technologies

view channel
Image: The Leica DM2500 LED Microscope for clinical laboratories and research applications (Photo courtesy of Leica Microsystems).

New LED Microscope Completes Line of Clinical and Research Tools

A popular microscope used for both clinical and research applications is now available with LED illumination. The Leica (Wetzlar, Germany) DM2500 and DM2500 LED microscopes represent a class of tools... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.